Both the prototypic tricyclic antidepressant imipramine (IMI) and the herbal product St John's wort (SJW) can be effective in the treatment of major depressive disorder. We studied hypothalamic gene expression in rats treated with SJW or IMI to test the hypothesis that chronic antidepressant treatment by various classes of drugs results in shared patterns of gene expression that may underlie their therapeutic effects. Individual hypothalami were hybridized to individual Affymetrix chips; we studied three arrays per group treatment. We constructed 95% confidence intervals for expression fold change for genes present in at least one treatment condition and we considered genes to be differentially expressed if they had a confidence interval excluding 1 (or À1) and had absolute difference in expression value of 10 or greater. SJW treatment differentially regulated 66 genes and expression sequence tags (ESTs) and IMI treatment differentially regulated 74 genes and ESTs. We found six common transcripts in response to both treatments. The likelihood of this occurring by chance is 1.14 Â 10 À23 . These transcripts are relevant to two molecular machines, namely the ribosomes and microtubules, and one cellular organelle, the mitochondria. Both treatments also affected different genes that are part of the same cell function processes, such as glycolytic pathways and synaptic function. We identified single-nucleotide polymorphisms in the human orthologs of genes regulated both treatments, as those genes may be novel candidates for pharmacogenetic studies. Our data support the hypothesis that chronic antidepressant treatment by drugs of various classes may result in a common, final pathway of changes in gene expression in a discrete brain region.
The search for new molecules and biological targets for antidepressant drug discovery remains a challenge for contemporary psychiatry. Such work is needed to understand the fundamental molecular mechanisms underlying major depressive disorder (MDD) and to identify new directions for treatment. The investigation of the mechanisms for the reported therapeutic activity of traditional herbal products, such as St John's wort (SJW) (see Figure 1 ), could uncover new mechanisms and novel treatments for MDD. SJW (hypericum) extracts are among the most widely used antidepressants in Germany with a market share of more than 25% in 1997. 1 Despite the controversy on the effectiveness of SJW as an antidepressant, the use of SJW has been widespread and several preparations containing SJW are commercially available in Europe and in the US. Even though two recent multicenter trials in the USA have failed, 2, 3 randomized clinical studies have shown that SJW extracts are significantly superior to placebo and similarly effective as standard antidepressants in the treatment of mild to moderately severe depression. [4] [5] [6] Significant drug interactions have been reported with cyclosporine and protease inhibitors, 7, 8 but a commonly cited advantage of SJW continues to be its favorable side effect profile. Although reports of serious and potentially fatal adverse reactions are known, and probably underreported, 9 the majority of significant side effects described in clinical trials are considered mild to moderate or transient.
Preclinical studies suggest that SJW is effective in three major biochemical systems relevant for antidepressant activity: inhibition of the synaptic reuptake of serotonin, noradrenaline, and dopamine; [10] [11] [12] it also produces monoamine reinhibition and longterm changes in receptors. 10 However, there is controversy as to the exact mechanism of action for the antidepressant effects of SJW. It is probable that both hypericin and hyperforin have antidepressant properties. Hypericin inhibits monoamine oxidases (MAO-A and MAO-B) and the antidepressant property of hyperforin has been attributed to its capacity to increase the extracellular levels of the monoamines and glutamate in the synaptic cleft, probably as a consequence of uptake inhibition.
11,13-15 SJW extracts contain six major natural product groups that may contribute to their pharmacological effects [acylphloroglucinols, biflavones, naphthodianthrones (hypericin), flavonol glycosides (hyperforin), proanthocyanidins, phenylpropanes, proanthcyanidins, and phenylpropanes]; 16 therefore, compounds other than hypericin or hyperforin could also contribute to the antidepressant effects of hypericum. Repeated oral administration of SJW for 3 consecutive days has been reported to ameliorate behavior observations in some animal models of depression, 14 and only recently the effects of long-term administration of SJW have started to be explored. 15 Our hypothesis has been that there may be common final molecular pathways that underlie the response to various types of antidepressant treatment. The identification of transcripts that are regulated in the hypothalamus by prolonged administration of either imipramine (IMI) or fluoxetine treatment has supported this hypothesis. 17 Several investigators studying mood-stabilizing drugs have used this strategy of a presumed final common pathway of action. [18] [19] [20] The hypothalamus was used in this study because key biologic manifestations of MDD include alterations in the hypothalamic functions that regulate food intake, libido, circadian rhythms, and the synthesis and release of hypothalamic neurohormones. 21 Patients with MDD, with melancholic features, typically have decrease appetite, decreased sexual interest, early morning awakening, diurnal variation in mood, and endocrine abnormalities, such as hypogonadism, hyposomatotropism, and hypercortisolism. 22 Additionally, several antidepressants, including extracts of SJW, when administered in a long-term basis downregulate corticotropin-releasing hormone gene (CRH) expression in the paraventricular nucleus of the hypothalamus (PVN). 15, [23] [24] [25] Here, we describe common transcripts in the hypothalamus related to the long-term administration of IMI and SJW. We identified human orthologs for genes that are regulated both by SJW and by IMI, as they may be potential novel candidates for pharmacogenetic studies. The ability to map rat genes to their cognate human genes provides a needed bridge between basic science and clinical research.
Material and methods

Hypericum extracts
The SJW extract was prepared by Botanicals Internationals (Long Beach, CA, USA) and generously donated to us. Hypericum perforatum native plant was extracted in ethanol/water at a ratios of 3-6 : 1, dried, and stored protected from light and moisture at 41C. All SJW extract used in this study came from a single lot and was free of pesticide, heavy metals, and microbiological contaminants. The SJW extract was analyzed at the initiation and every 6 months thereafter. High-performance liquid chromatography (HPLC) analysis of SJW was performed by the Pharmanex Research Center (Redwood City, CA, USA), and the extract we used had the following composition: total hypericins 0.33%; hypericin and pseudohypericin 0.013%; hyperforin 3.03%. The concentration and composition of other flavonoids in the SJW extract was not determined.
Animals
Studies were carried out in accordance with animal protocols approved by University of California, Los Angeles. Virus-and antibody-free male SpragueDawley rats (200-250 g, Harlan, Indianapolis, IN, USA) were housed 2/cage at 241C with lights on from 0600 to 1800. Animals were housed 3/cage in a stressfree environment for at least 5 days before the initiation of experimental procedures. This acclimatization period was used to minimize the effects of environmental and social stress in our experiments. Rats were randomly separated into four groups: saline (a control for IMI), carboxymethylcellulose (CMC, a control for SJW), IMI, or SJW groups. Animals treated with IMI (Sigma, St Louis, MO, USA) received 0.5 ml intraperitoneal (i.p.) injections daily for 8 weeks with 5.0 mg/kg drug dissolved in 0.9% saline. Animals treated with SJW extract were gavaged daily, for 8 weeks with 120 mg/kg, in 1 ml of 0.3% CMC (Sigma) in distilled water. CMC has been used to dissolve SJW as described previously. 14, 26 Control animals consisted of rats injected with vehicle (0.9% saline) i.p. for the IMI-treated group or gavaged with vehicle (0.3% CMC) for the SJW-treated group. Long-term administration has been utilized because of the welldocumented findings that antidepressants are generally effective after 3-6 weeks of administration. 24 Animals received their last treatment 24 h before termination of experiments. To prevent the confounding effects of stress on gene expression, animals were removed from their home cages by an animal handler not involved in the decapitation process and were decapitated within 45 s of individual removal from home cages. Immediately after sacrificing the animals, brains were removed. To avoid possible confounding variations caused by circadian rhythms, all animals were sacrificed at 10:00 to 12:00 noon. All hypothalamic tissues were dissected by the same investigator (M-L W), frozen, and stored at À801C.
Microarray studies
The following groups of animals were studied: (1) saline; (2) CMC; (3) IMI; and (4) SJW. Total RNA was extracted from each hypotamus using TRIzol (Qiagen, Valencia, CA, USA) reagent, cleaned with RNeasy (Qiagen), and its quality was verified by gel. Total RNA from individual hypothalamus was used for each array; three animals per group were studied. We used three to five array experiments per group. Dchip software 27 was used to do a stringent quality control of our arrays; array data that did not pass our quality control were not used in our analyses. Array experiments were repeated until three arrays per group met our quality control requirements, with three independent replications of our microarray experiments as recommended by Lockhart and Barlow. 28 Protocols recommended by Affymetrix Inc. (Santa Clara, CA, USA) were followed. Briefly, 15 mg of each RNA sample pool were submitted to reverse transcription with SuperScript Choice System (Gibco BRL, Rockville, MD, USA) and a T7-(dT)24 primer, followed by in vitro transcription and biotin-labeling with the Enzo BioArray High Yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA). Labeled cRNA was fragmented and 15 mg of the fragmented cRNA of each sample was used for hybridization in a 2-(N-Morpholino) ethanesulfonic acid-based buffer containing bovine serum albumin, herring sperm DNA, control oligonucleotide B2, and Eukaryotic hybridization controls BioB, BioC, BioD, and Cre (Affymetrix). We used GeneChip Rat Genome U34A arrays (Affymetrix), which contain sequences for 8799 genes and expressed sequences tags (EST). The samples were hybridized at 451C for 16 h under constant rotation. After the hybridization, microarrays were washed, stained with streptavidin phycoerythrin, and scanned in a GMS 418 Array Scanner (Affymetrix).
Data analysis: statistical methods
Microarray image files were loaded into the Dchip software package. This package implements the Li & Wong algorithm and computes two summary measures for each gene. 27 The first measure is the modelbased expression index (MBEI) that summarizes the approximate expression level over the 20 individual probes. The second measure is the present/absent call. This call is a decision rule utilizing a number of details of the probe pairs to determine if there was or was not any mRNA corresponding to that particular gene in the sample. The data set had 8799 genes. Our analysis plan consisted of three filtering steps to identify a list of differentially expressed genes. Genes were filtered in both of the treatment vs. control separately. The first step of the analysis was to remove genes that were absent in all arrays in all four of the conditions (two treatments Â two controls). This step removed 3051 genes from the analysis.
Step two involved the construction of 95% confidence intervals for the expression fold-change for each of the remaining 5748 genes. The expression fold-change value is a ratio between expression values in treatment and control conditions, thus fold-change of 1 or À1 is not different. Only those genes that had confidence intervals excluding 1 (or À1) were included in the final gene lists.
Step three excluded genes where the absolute difference between conditions was less than 10 (the median expression across the arrays was 55). This last step helps remove genes with very low levels of expression in which the foldchange can be large due to very small expression differences.
The Dchip software provides automated quality control by determining the genes or probes that are outliers. These outliers are treated as missing data in the subsequent data analysis steps. Dchip suggests that chips with greater than 5% outliers are of poor quality and should be repeated. In our study we found three chips to have greater than 5% outliers and these experimental conditions were re-run on new chips.
Microarray-based experiments involve exceedingly more measurements than samples even in experiments containing the largest practical sample size. In a recent review, Slonim discussed the difficulties of extracting meaningful information out of array data. Unfortunately, there is no 'one-size-fits-all' solution for the analysis and interpretation of wide expression array data. 29 In fact, data analysis techniques for microarray are still in the early phases of development. 30 Bonferroni method, one proposed solution to the multiple comparisons problem, requires the use of statistical test with known distribution and offers a conservative method for significance assessment. 31 The implementation of Bonferroni method to array analyses is generally not appropriate and it yields overly conservative critical values; therefore, alternative solutions to the multiple comparisons problem have been used. 32 Furthermore, methods for P-value correction are not generally appropriate for exploratory data analysis as false negatives are of potentially greater concern than false positives. Our analyses are comparable to those performed in many studies that measured differential expression by the ratio of expression levels between two samples; in which genes with ratios above a fixed cutoff were said to be differentially expressed. [33] [34] [35] [36] [37] [38] The advantage of our method is that the Li & Wong algorithm estimates the standard error of the expression measurement, which allows us to make statistical statements about the fold-change rather than simply using a predetermined cutoff. 27 Final gene lists were functionally classified using the batch query in the NetAffxt Analysis Center on the affymetrix website (http://www.affymetrix.com/ analysis/index.affx). Probability calculations were carried out to understand the likelihood of finding genes and ESTs common to the list of transcripts that were differentially regulated by IMI and SJW. In these calculations, we excluded genes that were absent in all conditions; therefore, we calculated the probability of finding six common genes in lists of 66 and 74 randomly selected group of genes from a total of 5748 genes.
Hierarchical clustering was performed using CLUS-TER and TREEVIEW software 39 on the sets of genes that had significant treatment fold changes. Genes and arrays were clustered using Average Linkage Clustering. Expression values in the cluster diagrams were standardized by subtracting the mean expression and dividing by the standard deviation.
Human ortholog and SNP identification
Rat genes were mapped to their human orthologs using a combination of web based databases and sequence alignment tools. We mapped orthologs across genomes using one or more locus specific identifiers as a foreign key in the LocusLink database (http://www.ncbi.nlm.nih.gov/LocusLink/). Many rat genes have obvious human orthologs, but in some instances, some rat genes could not be mapped to a human ortholog using Locus Link. We used at least two independent computational sequence comparison methods for genes that we could not map using LocusLink. Single-nucleotide polymorphisms (SNPs) were identified by querying the dbSNP database, (http://www.ncbi.nlm.nih.gov/SNP/), via a web interface available on Locus Link.
Results
We used an expression profile approach to compare transcriptional changes related to prolonged administration of IMI and SJW. Transcripts that were significantly altered by IMI and SJW treatments are presented in Figures 2 and 3 , respectively; these figures show the cluster analyses of our results. Table 1 lists all the transcripts significantly changed by either treatment grouped by functional classification. Our findings are compatible with a predominance of downregulation after chronic IMI, but not after SJW treatment.
Microarray analyses
Our analysis filtered out 66 genes as differentially expressed in the SJW versus CMC (control) comparison and 74 in the IMI versus saline comparison. Six genes were found to be common in the two lists of genes with a significant fold change. We calculated the probability that this was due to chance alone. The probability of finding one gene in common in two randomly selected lists of genes (n ¼ 66 and 74) is 0.00015, hence the probability of finding six genes in common is 1.14 Â 10
À23
. Four of those six transcripts were similarly downregulated, one transcript was similarly upregulated and another one had different regulation. Figure 4 shows the cluster analysis of these common genes. The ribosomal proteins S29 (X59051) and S4 (X14210); rat long interspersed repetitive DNA sequence LINE3 (M13100); and EST202275 which is similar to the sequence of the complete mitochondrial genome of the R. novergicus were downregulated in both IMI and SJW treatments; microtube-associated protein 1A (MAP1A, M83196) was upregulated; and rat carnitine palmitoyltransferase Ib (AF063302) was downregulated by SJW and upregulated by IMI treatment.
The functional classification of transcript revealed that differentially regulated genes and ESTs for SJW and IMI could be separated into 12 main functional groups, namely genes related to the following process: calcium, cell structure, energy production/expenditure, fatty acid metabolism, hormonal, ion concentration, neurotransmission, protein synthesis/ degradation, repetitive DNA sequences, signal transduction, synaptic transmission, and transcription regulation. Genes that could not be classified in those categories were included in miscellaneous. Several genes in the same pathway can be modulated by one of the treatment drugs (Table 1) . Also, different genes in the same pathway can be modulated by different antidepressant treatments. A very illustrative example of this phenomenon is our findings involving elements of the synaptic transmission: three genes are modulated by IMI and other three different genes are modulated by SJW (Table 1) .
Human ortholog identification A number of rat genes, including ribosomal protein S29, ribosomal protein S4, and MAP1A, was readily mapped to their associated human genes through Locus Link using the OMIM (Online Mendelian Inheritance in man) identifier to query the Homologene ortholog database.
Homologene results for rat ribosomal protein S29 (GenBank identifier X59051), ribosomal protein S4 (identifier X14210), microtubule associated protein, including the Homo sapiens MAP1A, were also easily identified. The rat gene carnitine palmitoyltransferase (CPT) Ib is the ortholog of the human carnitine palmitoyltransferase 1B gene.
The rat long interspersed repetitive DNA sequence LINE3 (M13100) proved difficult to map to the corresponding human ortholog using gene identifiers alone, so we performed a BLAST search against the Non-Redundant (NR) Genbank protein database. None of the top 40 blast hits mapped to a human gene; among the best three scoring human hits was the human LINE-1, which belongs to the reverse transcriptase family. We are unable to unambiguously classify the human LINE-1 homolog as the ortholog of the rat LINE-3 gene.
Finally, we wanted to identify the human ortholog of the rat expressed sequence fragment, EST202275, which is annotated as having similarity to mitochondrial genome. The results of a BLAST query against the NR database at NCBI showed that none of the high scoring homologous sequences mapped to the human genome. We utilized the entire finished human genome sequence, including the mitochondrial genome, in another round of sequence comparison against the rat gene fragment using the indexed sequence comparison method called BLAT (available Figure 2 Cluster analysis of transcripts that were significantly altered by imipramine when compared to saline. In each treatment group, genes colored in red are upregulated and genes colored in green are downregulated when compared to the average gene expression across all conditions. The CMC and St John's wort groups have been included just as illustration here, as most of the genes in this cluster analysis were not significantly changed by St John's wort treatment (See Figure 4) . Note the predominance of downregulation after imipramine treatment. The dendogram of treatment clustering is displayed above the image and describes the degree of relatedness between treatment groups; the length of branches denotes the degree of similarity, short branches indicate high similarity. Active treatment groups are more similar between themselves when compared to control groups. Expression values were standardized by subtracting the mean expression across groups and dividing by the standard deviation. CMC, carboxmethylcellulose; IMIP, imipramine; SAL, saline; SJW, St John's wort.
at UCSC, http://genome.ucsc.edu/cgi-bin/hgBlat). The top three BLAT hits indicated strong homology to the rat sequence within a region of the mitochondrial genome as well as intervals within chromosomes 11. We focused on the human mitochondrial interval since the rat sequence was also associated with mitochondrial sequence. A gene within this region (AY029066) translates into a protein 24 amino acids in length, MAPRGFSCLLLLTSEIDLPVKRRA. By traversing the genomic annotation back to the transcript level, we were able to identify the locus as belonging to Humanin and the mitochondrial ribosomal 16S RNA.
SNP identification SNP information on the six genes that are regulated by SJW and IMI treatments is presented in Table 2 .
Discussion
This study focused on surveying a number of genes and EST to elucidate the molecular mechanisms of the action of antidepressants beyond the receptor level and to identify a presumed final common pathway of antidepressant action. Figure 5 synthesizes our approach to identify cellular functions and genes that are regulated by antidepressants of different classes. The identification of such Figure 3 Cluster analysis of transcripts that were significantly altered by St John's wort. In each treatment group, genes colored in red are upregulated and genes colored in green are downregulated when compared to the average gene expression across all conditions. The saline and imipramine groups have been included just as illustration here, as most of the genes in this cluster analysis were not significantly changed by imipramine treatment (See Figure  4) . The dendogram of treatment clustering is displayed above the image and describes the degree of relatedness between treatment groups; the length of branches denotes the degree of similarity, short branches indicate high similarity. Active treatment groups are more similar between themselves when compared to control groups. Expression values were standardized by subtracting the mean expression across groups and dividing by the standard deviation. CMC, carboxmethylcellulose; IMIP, imipramine; SAL, saline; SJW, St John's wort. genes is useful for neuroscience research, pharmacogenetic association studies, and drug development.
Several groups, including ours, have used stressfree animals to study the effects of chronic antidepressant treatment. 15, 17, 23, 24 This is useful in the understanding of chronic antidepressant effects, as nondepressed humans treated with antidepressants have been reported to have physiological responses to such treatments. 40 We expected that SJW would regulate many transcripts in a similar way to a prototypic antidepressant drug. Contrary to expectation, our study identified only six genes that are regulated by IMI and SJW in the hypothalamus, but we found that treatment with both IMI and SJW elicit transcripts that are important in the same cellular functions of building (ribosomal protein S4 and S29), scaffolding/intracellular transport (microtubuleassociated protein 1A), and fueling the cell (carnitine palmitoyltransferase Ib and EST202275). Although these findings require further confirmation, we discuss their relevance, as these transcripts are fair representatives of their respective functional groups. Antidepressant effect in the function of cell building-down regulation of ribosomal proteins mRNA: ribosomal protein S4 and S29 Several lines of evidence indicate that ribosomal RNAs are responsible for protein synthesis; therefore, ribosomal proteins could have been recruited during evolution to stabilize the configuration of ribosomal RNA and improve protein synthesis. 41 Thus, ribosomal proteins may also have extraribosomal functions, which are still largely unknown. Protein production is important for several cellular functions, and it is essential for cell proliferation and neurogenesis. Evidence that treatment with antidepressants can alter neuronal cell proliferation in vivo and in vitro has already been documented. In vitro experiments suggest that fluoxetine is capable of inhibiting and stimulating cell proliferation in non-neuronal cells. 42, 43 Prolonged treatment with fluoxetine increased neurogenesis in adult rat hippocampus, but in vitro findings showed a dual effect of antidepressant in cerebellar cell cultures. 44 The role possible of altered functioning of ribosomal protein in human disease is largely unexplored.
Antidepressant effect in the function of cell scaffolding/transport-upregulation of microtubule mRNA: microtubule-associated protein 1A(MAP1A) Microtubules have a crucial organizing role in all eucaryotic cells. A variety of accessory proteins bind to microtubules and serve various functions. MAPs can stabilize microtubules against disassembly or cross-link microtubules in the cytosol. MAP assemblies can be separated in two types, type I MAP (MAP1A and 1B) and type II (MAP2, 4 and Tau). Type I MAPs are large filamentous molecules found in axons and dendrites of neurons. Chronic but not acute treatment with desipramine inhibited microtubule assembly in vivo and the degree of phosphorylation of serine residues of MAP2 was significantly increased after chronic administration of desipramine without changes in the total concentration of MAP2. 45 Given that MAP2 and Tau are major cytoskeletal proteins in neurons, which are involved in the pathogenesis of Alzheimer's and other neuropsychiatric diseases, 46, 47 and that it is not uncommon that antidepressants are included in the treatment regimen of those conditions, a better understanding of the effects of antidepressant treatment on microtubule proteins would be relevant.
Antidepressant effect in the function of cell fueling: downregulation of EST202275 (similar to mitochondrial genome mRNA) and modulation of rat carnitine palmitoyltransferase Ib 1, 2, and 3 genes. Antidepressants can affect brain energy metabolism and substrate oxidation pattern. It has been long suggested that antidepressants may act by making more energy available to overcome the depressed stated. 48 Initial observations supported that treatment with desmethylimipramine for 7 days resulted in increase in glucose utilization in several brain areas, but that treatment for 28 days was inhibitory. 49 Data on oxidative energy metabolism suggest that IMI had a maximum stimulation of respiration in the brain mitochondria that was sustained after 1-and 2-week treatment. 50 It should however be noted that IMI at high concentrations can inhibit ATPase activity; 51 moreover, uncoupling effects on oxidative phosphorylation in rat liver mitochondria have been described with melipramine. 52 It is possible that the human ortholog of the gene represented in rat EST202275 is the mitochondrial 16S rRNA gene. This gene seem to also encode humanin, a unique oncopeptide that inhibits neuronal death by an antagonistic interaction with members of the apoptotic signaling machinery. 53 This finding would support the hypothesis that antidepressants might be neuroprotective agents, possibly exerting their neuroprotective effects through diverse cellular and molecular mechanisms.
Additional mitochondrial process can also be affected by antidepressants, such as monoamine oxidase activity and the oxidation of fatty acids. CNS and peripheral mitochondrial monoamine oxidase (MAO) are influenced by antidepressants. 54, 55 Long-term effects of several antidepressant drugs, including IMI, can inhibit brain mitochondrial MAO activities of MAO-A and MAO-B forms. 56 Oxidation of fatty acids in the mitochondria is initiated by a sequence of events, of which CPT I and CPTII are important elements. Mitochondrial b-oxidation of long-chain fatty acids produces a large amount of ATP; it is the main source of energy for skeletal muscle during exercise and for cardiac muscle, and during prolonged fasting. In our experiments, modulation of carnitine palmitoyltransferase Ib 1,2, and 3 genes by SJW and IMI treatments were of opposite effect. It has been known that antidepressants disturb lipid turnover in different cell types, such as lymphocytes, monocytes, and human histiocytic lymphoma cell line U-937. 57, 58 There is evidence that mitochondrial DNA polymorphisms may increase the susceptibility to Alzheimer disease, indicating that mitochondrial function might be relevant to a psychiatric phenotype. [59] [60] [61] Repeated DNA sequences: long interspersed elements (LINE) Rat LINE3 (or L1Rn) was included among the few genes that were differentially regulated by chronic antidepressant treatment with both IMI and SJW. This gene belongs to a family of repetitive DNA elements, which is ubiquitous in mammals, namely the L1 family. Rat LINE3 has six putative open reading frames; the functions of these putative proteins are unknown. About 50 000 copies of L1 elements occur in the human genome, it accounts for about 5% of the total human DNA. L1 elements transpose through reverse transcription of an RNA intermediate. 62 Given that over 40% of the mammalian genome can be composed of repetitive elements of four major classes, could it be predictable that repetitive DNA sequences would be implicated in paradigms involving long-term treatments? The function of most families of repeated DNA is unknown: only 1-2% of those correspond to families of known function (ribosomal RNA, histones).
Intriguingly, the theme of repeated DNA sequences is present in a significant proportion of differentially regulated transcripts. For instance, several copies of ribosomal proteins sequences can be found in the genome. Several copies of the mitochondrial DNA genome are located in the mitochondrial matrix; each cell contains hundreds of mitochondrias and thousands of mtDNA copies. Type I MAP has several repeats on the amino-acid sequence KKEX, which is implicated as a binding site for tubulin.
Additional relevant systems identified by the functional characterization of differentially regulated genes As we focused on hypothalamic tissue, it should not be surprising that our results have not shown many significant changes in classical neurotransmitter systems. Nevertheless, our results support the concept that the cellular and molecular effects of antidepressants might involve neurohormones (vasopressin, growth hormone-releasing factor, proenkephalin, pituitary glycoprotein hormone alpha subunit, and promelanin-concentrating hormone), neuroimmune factors (transthyretin, thymosin beta-10, prothymosin alpha), glutamate (N-methyl D-aspartate 2A receptor), metabolic pathway (glycolytic) genes, protein synthesis and degradation (proteasome) and synaptic function (SC2 synaptic glycoprotein, synaptojanin 1, synaptosomal associated protein (SNAP-25A), syntaxin 1a and 2, and vesicle-associated membrane protein 1) (refer to Table  1 ). Interestingly, differential expression of vesicleassociated membrane protein 2 (VAMPs/synaptobrevin-2) has been found after antidepressant and electroconvulsive treatment in rat frontal cortex. 63 Additionally, signaling and calcium-related components appear to be modulated by long-term antidepressant treatment. These systems have been recently implicated in the pathophysiology of major depression and in the mechanism of action of antidepressant drugs. 21, 64 Transcriptional regulation The changes in gene expression that are observed in response to both acute and chronic antidepressant treatment provide insight into the underlying regulatory networks that modulate neural plasticity necessary to respond to chronic stress and subsequent depression induced by such chronic stress. The results of chronic antidepressant treatment ought to be conceptualized in the context of the transcriptional regulators, which ultimately mediate the observed changes in gene expression. Specific effects of antidepressants or electroconvulsive treatment have already been reported for immediate early genes and transcription factors such as c-fos, zif268, NGF1-A, phosphorylation of CRE-binding protein, DfosB, and Narp. [65] [66] [67] [68] [69] [70] [71] [72] In our analysis, we identified four genes that were downregulated in response to both IMI and SJW. Such genes could be potential markers for predicting response to antidepressant treatment; however, the fact that genes are coordinately downregulated suggests there are specific combinations of transcriptional regulators that control the expression of these four genes. Even though the transcription factors themselves may not exhibit significant differences in expression levels, changes in their ability to regulate gene expression can still occur. We have identified four transcription factors that undergo changes in expression specifically in response to IMI. Of these four transcription factors, AI23025 is a known inhibitor of DNA binding via dominant-negative effects that prevent other transcription factors from building a suitable scaffold for the recruitment of polymerase.
Additionally, the combination of transcription factors, including a known repressor, in combination with the modulation of other genes, including humanin, which inhibits specific pathways, such as apoptosis, suggests a real shift in the genetic program after antidepressant treatment. Chronic antidepressants may modify the expression levels of genes known to antagonize various pathways and cellular systems.
These results represent the net changes of many cell types present in hypothalamic tissue; therefore, it is not unexpected that most of the changes we identified are below two-fold. It was not within the scope of this work to replicate the relatively small changes of CRH gene expression in specific hypothalamic areas, such as in the PVN (reduction of 40%) that have consistently been reported after chronic antidepressant or SJW treatment. 15, [23] [24] [25] Of note, two transcripts that displayed large downregulation belong to the immune/inflammation related group; they are the transthyretin (for IMI treatment) and the interleukin-3 beta subunit (for SJW treatment) genes.
The findings reported here do not replicate those reported by Landgrebe et al. 73 as they characterized the effects of treatment with mirtazapine or paroxetine in total brain RNA of mice using a customized microarray. Differences in study design could account for these discrepancies. We studied a specific brain region (hypothalamus), while they studied whole brain; our study examined rats, theirs, mice. Finally, the duration of our long-term treatment (8 weeks) was different from the paradigm used in that study (1 or 4 weeks). In spite of these methodological differences, which preclude direct comparison of results, it is noteworthy that Landgrebe et al's data provide evidence that some antidepressants can predominantly downregulate gene expression, and that we found similar downregulation effects after chronic IMI treatment.
We need to consider the possibility that our results underreport actual changes because we did not focus on a specific neuronal nucleus; consequently, additional genes could be identified in future studies by adopting specific dissection strategies. Furthermore, as it is the case in most microarray studies, the number of genes queried in our study was disproportionally larger than the number of samples per group. To address that key issue, we used analyses approaches described in the literature to define differentially expressed genes. Further studies are needed to characterize the localization, time course, and intensity of changes we report here. It is unclear how many of these changes in mRNA will reflect into protein expression and be functionally relevant.
A novel observation emerging from this study is that several essential general cell functions may be affected by chronic antidepressant treatments (see figure 5 ). These functions include protein synthesis and degradation, cellular scaffolding and intracellular transport, mitochondrial and glycolytic energy metabolism, and cellular signaling through modulation of calcium biding proteins. Pathways that may be modulated by chronic antidepressant treatments include functions that may protect neurons from cellular injury. Our experiments provide a framework for the changes that occur during long-term administration of hypericum and IMI. It is possible that the regulation of genes in the same functional group could result in the same final outcome along a signaling pathway. These findings could form the basis of subsequent bioinformatics investigations into the pathways underlying both the progression and treatment of depression.
The ability to understand the results of microarray experiments and translate them into novel tools and targets for advancing the state of knowledge in the study of depression and response to antidepressant treatment can be greatly enhanced by identifying neuronal signaling pathways. Such models could serve as a framework for testing our hypotheses and refining them where necessary. The lack of complete understanding requires model building and hypothesis testing. The fact that several of the genes identified in this study contain dense numbers of SNPs is exciting because those SNPs may represent potential new candidates for the pharmacogenomic assessment of the phenotype of antidepressant treatment response. The combination of carefully planned genetic screens and informatics mining of expression data to extend and complete candidate pathways can eventually lead to the development of a new generation of treatment strategies and possibly diagnostic approaches for depression.
